BioNTech logo” title=”BioNTech logo” class=”companylogo”/>Squarepoint Ops LLC raised its position in BioNTech SE ((NASDAQ:(BNTX))) by 142.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,233 shares of the company’s stock after purchasing an additional 12,484 shares during the period. Squarepoint Ops LLC’s holdings in BioNTech were worth $1,731,000 as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of the business. Captrust Financial Advisors increased its position in shares of BioNTech by 433.3% during the fourth quarter. Captrust Financial Advisors now owns 400 shares of the company’s stock worth $33,000 after acquiring an additional 325 shares in the last quarter. Highlander Capital Management LLC bought a new stake in shares of BioNTech during the third quarter worth $35,000. US Bancorp DE bought a new stake in shares of BioNTech during the fourth quarter worth $46,000. Comerica Bank increased its position in shares of BioNTech by 5.1% during the fourth quarter. Comerica Bank now owns 12,852 shares of the company’s stock worth $1,394,000 after acquiring an additional 621 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in shares of BioNTech during the fourth quarter worth $51,000. 10.75% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently issued reports on (BNTX) shares. SVB Leerink increased their price objective on shares of BioNTech from $97.00 to $106.00 and gave the stock a “market perform” rating in a research report on Thursday, February 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $104.00 target price on shares of BioNTech in a research report on Wednesday. Berenberg Bank reaffirmed a “buy” rating and issued a $130.00 target price on shares of BioNTech in a research report on Wednesday. Canaccord Genuity raised their target price on shares of BioNTech from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, December 14th. Finally, Zacks Investment Research raised shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Tuesday, March 30th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $101.56.
NASDAQ (BNTX) opened at $113.87 on Friday. The firm has a 50-day moving average of $106.11 and a 200-day moving average of $99.38. The stock has a market cap of $27.42 billion, a PE ratio of -56.94 and a beta of -1.74. BioNTech SE has a 52-week low of $37.00 and a 52-week high of $131.00.
BioNTech ((NASDAQ:(BNTX))) last posted its earnings results on Monday, March 29th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $2.13. BioNTech had a negative net margin of 250.12% and a negative return on equity of 66.72%. On average, equities analysts anticipate that BioNTech SE will post -1.74 EPS for the current fiscal year.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer.
See Also: Can individual investors take part in an IPO?
Receive News & Ratings for BioNTech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNTech and related companies with MarketBeat.com’s FREE daily email newsletter.